Combination of farnesyl-transferase inhibition with KRAS G12D targeting breaks down therapeutic resistance in pancreatic cancer

• Päätekijät: Eszter Molnár (Tekijä), Marcell Baranyi (Tekijä), Krisztina Szigeti (Tekijä), Luca Hegedűs (Tekijä), Fanni Bordás (Tekijä), Zsófia Gábriel (Tekijä), Gréta Petényi (Tekijä), József Tóvári (Tekijä), Balázs Hegedűs (Tekijä), József Tímár (Tekijä)
• Aineistotyyppi: Kirja
• Julkaistu: Frontiers Media S.A., 2024-12-01T00:00:00Z.
• Aiheet: article
• Linkit: Connect to this object online.

Pancreatic adenocarcinoma is one of the deadliest forms of cancer with no effective therapeutic options. A KRAS mutation can be found in up to 90% of all pancreatic tumors, making it a promising therapeutic target. The introduction of new KRAS inhibitors has been a milestone in the history of KRAS m...